Replies to post #427234 on Anavex Life Sciences Corp (AVXL)

[abew4me]

Yes it most certainly is.

Once A2-73 has obtained FDA approval for Rett, that is the disease the FDA has assigned to that drug.

Therefore, if Anavex plans to submit an NDA using A2-73 for Fragile X (or any other disease) without conducting a P1 or P2, then they are in fact repurposing that drug.